Stocks of Novo Nordisk ADR (NYSE:NVO) traded higher last session on Wall Street, down -1.49% to $105.32.
NVO stock price is now -11.62% away from the 50-day moving average and -17.89% away from the 200-day moving average. The market capitalization of the company currently stands at $351.60B.
With the price target of $156, Goldman recently initiated with Buy rating for Novo Nordisk ADR (NYSE: NVO). On April 12, 2024, BMO Capital Markets recently initiated its ‘Outperform’ rating on the stock quoting a target price of $163, while ‘Morgan Stanley’ rates the stock as ‘Overweight’
A total of 0.02% of the company’s stock is owned by insiders.
During the past 12 months, Novo Nordisk ADR has had a low of $94.73 and a high of $148.15. As of last week, the company has a debt-to-equity ratio of 0.47, a current ratio of 0.94, and a quick ratio of 0.75. According to the stock market information, the enterprise value for the company is $451007250432, which is based on a 34.15 price-to-earnings ratio, a 3.10 price-to-earnings-growth ratio, and a beta of 0.41. The fifty day moving average price for NVO is $119.1636 and a two-hundred day moving average price translates $128.2626 for the stock.
The latest earnings results from Novo Nordisk ADR (NYSE: NVO) was released for 2024-09-30. The net profit margin was 35.03% and return on equity was 88.20% for NVO. The company reported revenue of $10.51 billion for the quarter, compared to $8.57 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 22.58 percent.
